BEIJING, July 8, 2024 /PRNewswire/ — DP Technology, an “AI for Science” paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer’s disease (AD).

AD is the most frequent cause of dementia (60%~70%), affecting approximately 57 million people worldwide. Neurovascular dysfunction is an early and predominant event in AD development, independent of classic amyloid pathology. Lp-PLA2 is a phospholipase secreted primarily by inflammatory cells, including peripheral macrophages and CNS microglia. It hydrolyzes oxidized phospholipids typically on low-density lipoprotein (LDL), producing lysophosphatidylcholine (lysoPC) and other potent proinflammatory factors. LysoPC is a key inflammatory mediator on vascular endothelial cells, causing vascular pathology including vessel leakage and BBB damage. The inhibition of Lp-PLA2 by Rilapladib significantly slowed down AD progression and repaired BBB damage in a Phase IIa trial.

DPT0416 is a novel CNS-penetrable Lp-PLA2 inhibitor, exhibiting higher potency, better ADME and physicochemical properties than Rilapladib. In animal models, DPT0416 showed improvement in BBB integrity and a reduction in brain inflammation. The IND-enabling studies are ongoing.

“Alzheimer’s disease imposes increasing burdens on the world. Approvals of three anti-amyloid β (Aβ) antibodies mark a pivotal moment in the fight against AD, but the modest clinical efficacy and side effects highlight the complexity of AD and call for more novel interventions with better efficacy. The future treatment of AD should address multiple aspects of the disease, including anti-oxidants, anti-inflammation, and enhancing brain resilience, among others,” said Xiaomin Zhang, Head of Drug Discovery at DP Technology. “Targeting Lp-PLA2 is a novel therapy that addresses multiple factors beyond amyloid. Given rilapladib’s positive clinical results, the better molecule DPT0416 is expected to bring more benefits to AD and dementia patients.”

“DP Technology is revolutionizing the AI for Science landscape by integrating ‘AI + Simulation + Experiments’ into our processes to address significant medical needs,” said Weijie Sun, Founder and CEO of DP Technology. “The successful identification of DPT0416 highlights the power of our RiDYMO® platform, particularly the contributions of the Uni-FEP and Uni-QSAR modules in enhancing molecular interactions, drug-like characteristics, and BBB penetration. These real-world applications of our cutting-edge algorithms signify an important progression towards our envisioned future. We look forward to forging partnerships with trusted collaborators to advance this initiative to the next pivotal stage.”

The RiDYMO® drug design platform integrates various AI and physical algorithms, dedicated to the development of drugs for “undruggable” targets and “best-in-class” molecules. As one of its core algorithms, Reinforced Dynamics (RiD) has a significant advantage in the sampling efficiency of molecular dynamics simulation. By fully leveraging the high-dimensional representation capabilities of neural networks, RiD can efficiently capture dynamic conformational changes in complicated biomolecular systems.

The RiDYMO® platform is dedicated to studying the dynamics of biological systems and revealing cryptic binding sites, encompassing a range of challenging systems including protein-protein interactions (PPIs), intrinsically disordered proteins (IDPs), membrane proteins, RNA, and others. Its effectiveness has been confirmed through validation on challenging targets, including the c-Myc protein, c-Myc RNA, GPX4 protein, Kv1.3 protein, and others.

About DP Technology

DP Technology, an “AI for Science” new paradigm-driven company, dedicated to applying Artificial Intelligence and Molecular Simulation algorithms to solve important scientific problems by combining advanced computational methods.

Relying on DP Technology’s Dynamics-based drug design platform, RiDYMO®, we have set up a world-leading hit discovery platform. The team has established external collaborations and built up strong internal pipeline, focusing on three areas of CNS, oncology and autoimmune diseases.

For collaboration and further information，please contact Dr. Xiaomin Zhang (zhangxm@dp.tech). 

References:
[1] Alzheimers. Dement. 17(Suppl 10), e051496 (2021).
[2] Nat. Med. 25, 270-276 (2019).
[3] Med. Res. Rev. 40, 79-134 (2020).
[4] Alzheimers. Dement. 1, 131-140 (2015).
[5] Diab. Vasc. Dis. Res. 14, 200-213 (2017).

Source

ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological malignancies, announced today that its novel BCR-ABL1 tyrosine kinase inhibitor (TKI), olverembatinib, has been approved by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region (SAR) of the People’s Republic of China for the treatment of adult patients with tyrosine kinase inhibitors (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP) harboring the T315I mutation; and adult patients with CML-CP resistant to and/or intolerant of first-and second-generation TKIs. This approval marks another major milestone for olverembatinib following initial approvals granted to the drug in the Chinese mainland for the above indications.

Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program, is the first third-generation BCR-ABL1 inhibitor approved by China’s National Medical Products Administration (NMPA). As a potential global best-in-class drug that can effectively target BCR-ABL1 and a spectrum of BCR-ABL1 mutants, including the T315I mutation, clinical trial results of olverembatinib have already been included in the National Comprehensive Cancer Network (NCCN) guidelines for the management of CML.^[1] Olverembatinib is being jointly commercialized in China by Ascentage Pharma and Innovent Biologics. All lead drug candidates are being studied as they are an investigational drug and not approved in the US.

“Olverembatinib has the potential to be a global best-in-class drug. We are glad that the drug is set to benefit patients with CML in Macau, China, with the approval marking another major milestone in the clinical development of olverembatinib,” said Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma. “Since its inception, Ascentage Pharma has steadfastly committed to its mission of addressing unmet clinical needs in China and around the world. We are confident that over time, olverembatinib and our other investigational drugs will bring greater benefits to more patients globally.”

Reference:

1. Shah N, Bhatia R, Altman JK et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Chronic Myeloid Leukemia Version 2.2024 (December 5, 2023). Available from: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. 

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a fully integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.

The company has built a pipeline of 9 clinical-stage drug candidates, including novel, highly potent Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation TKIs. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 clinical trials, including 6 global registrational Phase III studies, in the US, Australia, Europe, and China.

Olverembatinib, the company’s first lead asset developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product in China, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted Orphan Drug Designations (ODDs) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU.

To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous leading biotechnology and pharmaceutical companies such as Takeda, AstraZeneca, Merck, Pfizer and Innovent ; and research and development relationships with leading research institutions such as Dana-Farber Cancer Institute, Mayo Clinic, MD Anderson Cancer Center, National Cancer Institute and the University of Michigan.

The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions and expectations or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions and expectations may alter in light of future development.

Source

HAIKOU, China, July 7, 2024 /PRNewswire/ — A report from Hainan International Media Center (HIMC):

From July 4-6, a delegation from China’s southern Hainan Province held Hainan Free Trade Port (FTP) related promotion and exchange activities in Switzerland, cementing cooperation in the fields of medical health, education, and high-end shopping & consumption.

During their time in Switzerland, the Hainan delegation held discussions and research meetings with numerous important companies and institutions, including Merck, Richemont, Roche Diagnostics,  EHL Hospitality Business School, Switzerland Global Enterprise, the World Trade Organization, and the World Intellectual Property Organization.

Inviting Swiss counterparts to leverage the FTP’s preferential policies, Hainan is specifically promoting cooperation in the fields of medical health, independent school running, and intellectual property protection. Hainan also made a point of expressing their warm welcome to Swiss enterprises to take part in the 5th China International Consumer Products Expo in April, 2025.

Co-organized by Hainan’s provincial government and the Switzerland Global Enterprise, the Hainan Free Trade Port Medical & Health Industry Exchange Meeting was held in Zurich on July 4. The event was well-received, with nearly 50 representatives from well-known Swiss companies and industry associations (including the Swiss Medical Technology Association, the the Swiss Scientific and Industrial Pharmaceutical Association, Novartis, Nestlé Health Science, Sonova, Similasan, Alcon, and IBSA) in attendance.

At the meeting, the Swiss side affirmed that the Hainan FTP’s conducive business environment and preferential policies (especially the innovative measures in the Boao Lecheng International Medical Tourism Pilot Zone) mean that the island has broad development prospects in the medical and health industry. Lecheng has become the primary rapid access channel for global innovative medical products entering China, and many Swiss medical companies—in learning about how the FTP’s preferential policies support Lecheng—are now planning to deepen cooperation with Hainan.

The conference saw contract signings take place between Sonova & the Boao Lecheng International Medical Tourism Pilot Zone, Industrie Biomediche Insubri SA & Susheng Biotech, and Dr. Dünner AG & Winhealth Pharma. Also, to promote innovative development in life sciences and the medical health industries, Switzerland Global Enterprise signed a memorandum of understanding with the Hainan Provincial Bureau of International Economic Development.

Source

Presenting an Authentic and Immersive Macau Experience to Visitors Under One Roof

KUALA LUMPUR, Malaysia, July 5, 2024 /PRNewswire/ — Galaxy Macau™, The World Class Integrated Resort (“Galaxy Macau”), has been actively supporting and participating in Macau SAR Government’s promotional activities, and continuously working with the government and industry partners to expand international visitor sources. The “Experience Macao Malaysia Roadshow”, organised by the Macao Government Tourism Office, was officially launched on 5 July 2024 in Kuala Lumpur at Sunway Pyramid Shopping Mall. The four-day event (5 to 8 July) aims to showcase the diverse tourism products in Macau to international tourists, attracting travellers to choose Macau as a travel destination. Galaxy Macau is also shining with its exciting tourism products by presenting its unparalleled luxury offerings and its one-stop luxury resort experience as Asia’s leading destination for leisure, entertainment, dining, events and conferences.

Galaxy Macau proudly supports and aligns with the Macao SAR government’s efforts to extend Macau’s reach into the Southeast Asian market. The world-class integrated resort’s iconic booth at the Malaysia Roadshow, showcasing the grand landscape of the integrated resort. Visitors to the booth can not only enjoy the interaction and photo moment with the adorable GalaxyKidz mascot “Wavey” the Peacock at the photobooth, but also experience the unique charm of Macao’s “tourism+” offerings, reflecting Galaxy Macau’s commitment to promoting Macau as a World Centre of Tourism and Leisure.

There are also daily lucky draws during the roadshow where visitors can stand a chance to win prizes sponsored by Galaxy Macau.

Starting from MYR271++ per night, Galaxy Macau is offering roadshow-exclusive offers for stays between 12 July to 30 November 2024 from a selection of world class hotels – Andaz Macau, Broadway Hotel, Galaxy Hotel™, Hotel Okura Macau or Banyan Tree Macau. Booking period opens from 5 to 19 July 2024. Applicable to all five hotels, the offer includes free access to the Grand Resort Deck and free minibar, immersing guests in a comprehensive one-stop integrated resort experience.

A Macao Travel Trade Seminar & Minimart was also conducted at the Sunway Resort Hotel Ballroom on 4 July 2024 in conjunction with the “Experience Macao” Malaysia Roadshow, where guests were presented with the latest hotel information on Andaz Macau, Broadway Hotel, Galaxy Hotel™, Hotel Okura Macau, Banyan Tree Macau, and Galaxy International Convention Centre (GICC). 

Remaining the top integrated resort globally with the most Forbes five-star hotel honors under one roof – Galaxy Macau spans over 1.1 million square-meters and is renowned for its unparalleled mix of entertainment and leisure attractions that are unmatched in Macau. With 8 award-winning world-class luxury hotels to choose from, guests are spoilt for choice. Water sports enthusiasts can make a splash at the 75,000-square-meter Grand Resort Deck – the world’s leading skytop oasis. Foodies meanwhile can indulge in a selection of over 120 dining options, ranging from Michelin-starred establishments to local street food legends; a delectable selection that has earned Galaxy Macau the distinction of being Asia’s premier dining destination. For an authentic Asian street food adventure, guests can cross the link bridge to explore vibrant local and Asian cuisines at Broadway Food Street. Fashionistas will adore Galaxy Promenade, an award-winning shopping destination spread over 100,000 square-meters. Luxury flagship stores, designer boutiques and high-street labels contribute to over 200 world-renowned luxury fashion and lifestyle brands. For live performances and events, the 2,500-seat Broadway Theatre plays host to a diverse range of live shows, events and cultural activities from around the world with up-close and personal experiences. Galaxy Macau opened two world-class hotels – Raffles at Galaxy Macau and Andaz Macau, with GICC as its latest addition to the Group’s ever-expanding integrated resort precinct, ushering a new era for the MICE industry in Macau. GICC is a world-class event venue featuring 40,000 square-meters of total flexible MICE, and a 16,000-seat Galaxy Arena – the largest indoor arena in Macau. In April 2024, Galaxy Macau also announced the launch of Capella at Galaxy Macau,  further solidifying the destination’s undisputed reputation as Macau’s Ultimate Luxury Integrated Resort. 

Galaxy Macau has always adhered to its “World Class, Asian Heart” service philosophy to offer exceptional experiences for guests from all around the world. As the city gears up for a continuing wave of international tourism, Galaxy Macau looks forward to welcoming visitors with award-winning accommodations, unforgettable leisure experiences, and unparalleled shopping, dining and entertainment all under one roof. In the future, Galaxy Macau will continue to launch more world-class events to enhance Macau’s positioning as a World Centre of Tourism and Leisure.

More high-res images of the Experience Macao Malaysia Roadshow can be found in the virtual media kit.

About Galaxy Macau Integrated Resort 

Galaxy Macau™, The World-class Luxury Integrated Resort delivers the “Most Spectacular Entertainment and Leisure Destination in the World”. Developed at an investment of HK$43 billion, the property covers 1.1 million-square-meter of unique entertainment and leisure attractions that are unlike anything else in Macau. Eight award-winning world-class luxury hotels provide close to 5,000 rooms, suites and villas. They include Banyan Tree Macau, Galaxy Hotel™, Hotel Okura Macau, JW Marriott Hotel Macau, The Ritz-Carlton, Macau, Broadway Hotel, Raffles at Galaxy Macau, Andaz Macau. Unique to Galaxy Macau, the 75,000-square-meters Grand Resort Deck features the world’s longest Skytop Adventure Rapids at 575-meters, the largest Skytop Wave Pool with waves up to 1.5-meters high and 150-meters pristine white sand beach. Two five-star spas from Banyan Tree Spa Macau and The Ritz- Carlton Spa, Macau help guests relax and rejuvenate.

As the dining destination in Asia, Galaxy Macau offers a wide variety of gastronomic delights, exquisite experiences and ingredients of the finest quality with over 120 dining options from Michelin dining to authentic delicacies; Galaxy Promenade is the hottest shopping destination featuring the latest in fashion and curated experiences in Macau. Spanning over 100,000-square-meters, luxury flagship stores, lifestyle boutiques and our selection of labels are among the more than 200 world-renowned brands for a world-class shopping journey; Galaxy Cinemas, immersive thrills and luxurious comfort go hand in hand at Galaxy Cinemas. All 10 theaters are equipped with the latest audio-visual technology; CHINA ROUGE, one-of-a-kind deluxe lounge that evokes the glitz and glamor of Shanghai’s golden era with entertainment in luxury and style; and Foot Hub presents the traditional art of reflexology to make you feel more relaxed and revitalized. For Authentic Macau Flavours & Vibrant Asian Experiences, Broadway Macau – just a 90-second walk via a bridge from Galaxy Macau, has over 35 Authentic Macau & Asian Flavours at its Broadway Food Street. The 2,500-seat Broadway Theatre plays host to world-class entertainers and a diverse array of cultural events. Meeting, incentive and banquet groups are also well looked after with a portfolio of unique venues in Galaxy Macau and a professional service staff.

Galaxy International Convention Center (GICC) is the latest addition to the Group’s ever-expanding integrated resort precinct and will usher in a new era for the MICE industry in Macau. GICC is a world- class event venue featuring 40,000-square-meter of total flexible MICE, and a 16,000-seat Galaxy Arena – the largest indoor arena in Macau.

For more details, please visit www.galaxymacau.com, www.broadwaymacau.com.mo and www.galaxyicc.com

Source